Corrections and Updates
Last updated: October 25, 2026.
We want this site to be right. If we make a mistake, we fix it and say so.
Our policy
- Errors of fact (a wrong date, number, name, document or status) are corrected as soon as we confirm them, with a target of within 24 hours of a credible report.
- Corrected posts carry a note at the top, such as "Correction (date): we originally wrote X. The source says Y."
- Updates (new developments, status changes) are added as a dated "Updated" line, with the original text kept intact when practical.
- We do not quietly delete a factual error. If a post must be withdrawn, we say so and explain why.
- Typos and formatting may be fixed without a note.
How to report a problem
Use the Contact page or email cheapervetguide@mail.grokbot.com. Please include the post link, the sentence in question, and a link to a source that shows the problem. We cannot act on claims we cannot check.
Corrections log
| Date | Post | What changed |
|---|---|---|
| Oct. 25, 2026 | Where peptide regulation stands right now | Correction: we originally gave October 15, 2026 as the date the interim peptide policy reached White House review. OMB's reginfo.gov record shows a received date of 10/14/2026. October 15 is the date of the AP and CNBC reports. |
| Oct. 25, 2026 | Where peptide regulation stands right now | Correction: the timeline implied the next FDA advisory committee meeting concerned GHK-Cu only. FDA's page for that meeting lists five substances: LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF. |
| Oct. 25, 2026 | Where peptide regulation stands right now | Clarification: the February 6, 2026 statement is now attributed to then-FDA Commissioner Martin Makary (FDA's page lists his term as April 2025 to May 2026). |
We will list each correction in this table with its date. The Oct. 25 timeline post carries an "Updated October 25, 2026" note at the top.